Protocol Ledger

NCT03790865 · Phase II/III · TERMINATED

Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

Interventional Phase II/III clinical trial protocol NCT03790865 sponsored by Millendo Therapeutics SAS in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-25 Enrollment: 158 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03790865
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)158 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03790865
Protocol FieldVerified Registry Value
NCT IdentifierNCT03790865
Consolidated Lead SponsorMillendo Therapeutics SAS
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment158 participants (ACTUAL)
Registered Start Date2019-03-25
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI